Moreover, recent network pharmacology focusing on XYS showed that XYS exerted an improved effect on both diabetes and depression involving simultaneous regulation of multiple pathways, such as immune inflammatory reactions, insulin and its receptors (PI3K-AKT), and the cAMP signaling pathway [23]. This evidence concerns the gene INS and major depressive disorder.